Qianhong pharmaceutical enoxaparin sodium product is about to be approved for production

According to the information on CFDA's website on May 19, Qianhong Pharmaceutical (002550 SZ) changed its application status of enoxaparin sodium product to "approved - to be certified" Previously, the company said on the interactive platform that enoxaparin sodium APIs and preparations declared for production by the company had been inspected on site, and the approval may be relatively large The company hasn't received the notice yet, but it shouldn't be a big problem to get the approval, people told the big smart news agency today Insiders of the company have said that enoxaparin sodium is planned to be sold at home and abroad At present, the production and marketing plans have been arranged, "everything is ready but without approval" The company is actively developing overseas customers, in which a small number of products have been sold in the foreign market In the domestic market, small molecule heparin sodium APIs and preparations, such as enoxaparin, daparin and other low molecule heparin sodium APIs and preparations, will become a new profit growth point of the company if they can get the production approval smoothly Enoxaparin sodium is a kind of low molecular weight heparin, which is used to prevent and treat deep vein thrombosis or pulmonary embolism Qianhong pharmaceutical is mainly engaged in two series of products, i.e pancreatic kininogenase and heparin sodium The market share of heparin sodium API in Europe is 25% Heparin Sodium Injection has been ranked in the forefront for many years in China, and has certain brand awareness and scale advantages in this field.